U.S. Sexual Health Testing Market Size By Disease Type(Chlamydia, Trichomonas, Gonorrhea, HPV, HSV), By Type of Testing(Molecular Test, Immunology Assay, Culture/Isolation Of Organisms), By Sample Type(Blood Based, Urine Based, Oral-Fluid Based), By Device(Laboratory Devices and Point of Care (POC) Devices), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online), By Geographic Sco

U.S. Sexual Health Testing Market Size And Forecast

U.S. Sexual Health Testing Market size was valued at USD 23.3 Billion in 2024 and is projected to reach USD 43.69 Billion by 2031, growing at a CAGR of 7.49% from 2024 to 2031.

Sexually transmitted diseases are common and millions of new infections occur each year in the United States. Rising number of sexually transmitted diseases propelling the demand for sexual health testing near future. The U.S. Sexual Health Testing Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

U.S. Sexual Health Testing Market Definition

Sexual health testing is the combination of different tests and several different methods that are used for the diagnosis and detection of sexually transmitted diseases such as Chlamydia, Gonorrhea, Trichomonas, HIV, HSV, HCV, HPV, and rest of others. Four major types of testing including Culture/Isolation Of Organisms, Molecular Test, Immunology Assay, and others, are used for sexual health testing. HIV can be diagnosed through three types of HIV tests such as antibody tests, antigen/antibody tests, and nucleic acid tests (NAT).

The prevalence of STDs across the American population is growing with growing new cases each year. In addition to other sexually transmitted diseases (STDS), the rate of HIV per 100,000 people in the Mid-West region of the US. As shown in the above diagram, the population across Illinois is having highest new HIV diagnosis rate per 100,000 people across the state. In 2020, Illinois accounted for the new HIV diagnosis rate of 11.7 per 100,000 people.

It looks like STDs are becoming more common. Looking at the figure above, you can see that Chlamydia rates per 100,000 people in Kansas are elevated. In 2019, we saw 524.8 cases of Chlamydia per 100,000 Kansans, which thankfully dropped a bit to 505.3 in 2020. But, on a less positive note, Gonorrhea rates actually increased by almost 14% between those years! Specifically, Gonorrhea went from 169.3 cases per 100,000 in 2019 to 192.9 in 2020. These kinds of trends are really pushing the expansion of the US Sexual Health Testing Market, it seems.

U.S. Sexual Health Testing Market Overview

Sexually transmitted disease (STD), is also known as sexually transmitted infection. It can be defined as, a pathogen that causes infection through sexual contact, this recognizable condition is termed a sexually transmitted disease. Sexually transmitted diseases are common and millions of new infections occur each year in the United States. Rising number of sexually transmitted diseases propelling the demand for sexual health testing near future.

We're seeing a rise in Sexually Transmitted Diseases (STDs) across the United States, including things like Chlamydia, Gonorrhea, Trichomonas, Syphilis, HIV, Herpes Simplex Virus (HPV), Pelvic Inflammatory disease (PID), and HSV. The Center for Disease Control and Prevention (CDC) actually reports that STD cases are increasing every year. It's a bit scary, especially when you see how much syphilis and gonorrhea rates have gone up in the last ten years. The CDC thinks about one in five of us has a common STD at any given time. In just 2021, there were about 2.5 million reported cases of Chlamydia, Gonorrhea, and syphilis. And if you go back to 2018, there were around 68 million people with sexually transmitted infections. On top of that, roughly 1.2 million people in the US are living with HIV.

Okay, so it looks like there's a real opportunity for growth in this market, particularly with the growing awareness of sexual health issues driven by, unfortunately, rising cases of gonorrhea and syphilis. Early numbers from the U.S. Centers for Disease Control and Prevention indicate that syphilis, gonorrhea, and chlamydia are all on the rise. Get thisCDC stats revealed a 26% jump in syphilis cases between 2020 and 2021, with reported primary and secondary cases hitting at least 52,354. That's the highest we've seen since 1948 and the highest infection rate since 1991! And to top it off, the CDC is reporting that American Indian and Alaska Native communities are experiencing the highest rates of syphilis infections. Even though these STDs are more prevalent among men who have sex with men, overall, rates of chlamydia and gonorrhea still climbed by 4.4% between 2020 and 2021.

Now, what's on the horizon for sexual health testing? Well, there are definitely some hurdles. Lack of awareness and discrimination about sexual health, combined with rising fears about data privacy, data breaching, and confidentiality, could slow things down. Think about itSome folks might skip sexually transmitted disease testing because they're terrified their parents will find out. It's a legitimate fear! Confidentiality concerns can also keep young people from accessing sexual or reproductive health services in general. In fact, in the U.S., about 12.7% of sexually active young people covered by their parents' health insurance avoided sexual and reproductive healthcare because they didn't want their parents to know. And it's even more common among 15 to 17-year-olds, where a staggering 22.6% stayed away.

U.S. Sexual Health Testing Market Segmentation Analysis

The U.S. Sexual Health Testing Market is segmented based on Disease Type, Type of Testing, Sample Type, Device, And Distribution Channel.

U.S. Sexual Health Testing Market, By Disease Type

• Chlamydia• Trichomonas• Gonorrhea• HPV• HSV• HIV• HCV• Others

To Get Summarized Market Report By Disease Type-

So, when you think about the market, one way to slice it up is by Disease Type, and we're talking about things like Chlamydia, Trichomonas, Gonorrhea, HPV, HSV, HIV, HCV, and others. Right now, Chlamydia is really the one to watch – it's in the lead and predicted to keep growing around 7.89% annually. The thing is, you really want to catch it early. Untreated chlamydia can lead to serious complications like pelvic inflammatory disease (PID) and even infertility. The CDC reported about 1.5 million cases just in 2020! Luckily, you can now test for chlamydia from the comfort of your home with these mail-in kits. You usually collect a urine sample or use a swab, then send it off to a lab. If the home test is positive, a doctor may want to confirm it with a lab test. Companies like Everly Well, Inc, LetsGetChecked, Lemonaid Health, Nurx, MyLab Box, and STD Check in the U.S. offer these home-to-lab chlamydia tests.

U.S. Sexual Health Testing Market, By Type of Testing

• Molecular Test• Immunology Assay• Culture/Isolation Of Organisms• Others

When we talk about Type of Testing in the US Sexual Health Testing Market, we're looking at things like Molecular Tests, Immunology Assays, Culture/Isolation of Organisms, and a few other methods. Molecular Tests were the big players back in 2021, and honestly, we think they'll keep growing strong, at about 7.25% each year. Imagine Molecular human papillomavirus (HPV) assays – they're like tiny detectives, searching for viral DNA to see if HPV is around. Scientists have a whole range of tests they can use to find HPV. For example, there's the “Aptima® HBV Quant Assay” from Hologic Inc.; it's a molecular assay that helps with HBV treatment and uses a clever dual-target approach. In richer countries, they often use really precise Sexually Transmitted Infection (STI) diagnostic tests (you know, the kind that uses all that fancy molecular tech), which are great at spotting infections even before you feel anything. But, when it comes to chlamydia and gonorrhoea, these advanced tests are often unavailable in poorer countries.

U.S. Sexual Health Testing Market, By Sample Type

• Blood Based• Urine Based• Oral-Fluid Based• Others

Based on Sample Type analysis, the US Sexual Health Testing Market is classified into Blood Based, Urine Based, Oral-Fluid Based, and Others. Blood Based holds a highest market share in 2021 and is projected to grow with highest CAGR of 8.12% during the forecast period. The most commonly used sample type for the detection of sexually transmitted diseases is blood. Cells, chemicals, proteins, and other blood components can also be measured or examined through blood tests. A routine exam frequently includes blood work.

Additionally, blood samples are used toassist in the diagnosis of several illnesses and conditions. Blood samples are also used to check on a patient’s medical therapy progress for chronic diseases like diabetes or high cholesterol. Blood tests can diagnose many sexually transmitted infections, including hepatitis B, genital herpes, HIV, and syphilis. A blood sample is taken via venipuncture, dry blood spot, or capillary draw and delivered to a lab for testing to identify HIV.

U.S. Sexual Health Testing Market, By Device

• Laboratory Devices• Point of Care (POC) Devices

Okay, so when we're checking out the US Sexual Health Testing Market, and we break it down by device type, it basically splits into two groupsLaboratory Devices and Point of Care (POC) Devices. Back in 2021, Laboratory Devices were the big dogs, and guess what? We think they're going to keep growing like crazy – maybe even the fastest, with growth around 7.23% each year for the next little while. A huge part of that is all the cool, new molecular diagnostics coming out. When companies launch new products, it really helps labs get the instruments and gear they need to do their thing. Like, check out Qiagen Inc., they launched the NeuMoDxHSV 1/2 Quant Assay in May 2022, which helps labs measure and tell the difference between herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). By making tests like that, Qiagen is expanding what labs can offer, and that ultimately helps the whole market grow because of these advanced testing options.

U.S. Sexual Health Testing Market, By Distribution Channel

• Hospital Pharmacies• Retail Pharmacies• Online• Others

To Get Summarized Market Report By Distribution Channel-

When you look at where people get tested in the US, the Sexual Health Testing Market breaks down into a few key areasHospital Pharmacies, Retail Pharmacies, testing done Online, and a category for "Others". In 2021, Hospital Pharmacies were the biggest player, and they're expected to keep growing, with a projected growth rate of 7.61% – the highest of all the channels! Since many people get tested at hospitals after seeing a doctor, demand for STD testing is likely to keep climbing. Plus, people trust the accuracy of lab tests that are common in hospitals.

Hospital pharmacies play a big role too. They're not just dispensing medications; they're carefully managing how drugs are used to improve patient care. And with people preferring hospitals for clinical testing of sexually transmitted diseases, especially tests for common conditions like gonorrhea, HIV, and chlamydia, it all adds up to strong growth for this segment.

Key Players

The major players in the market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Quest Diagnostics Incorporated., and Others.

This section provides a company overview, ranking analysis, company regional and industry footprint, and

Key Developments

• In December 2022, Thermo Fisher Scientific, launched the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases

• In May 2022, Alinity m STI Assay has been approved by the FDA, according to an announcement from Abbott. The test simultaneously identifies and differentiates four sexually transmitted infections (STIs). Untreated STIs can result in serious health issues, such as an increased chance of developing certain malignancies and infertility

• In December 2021, for use on the cobas 5800 System in countries that accept the CE Mark, Roche launched the first infectious disease assays as well as the cobas omni Utility Channel. These will be the first tests made available for use on the brand-new cobas 5800 System to assist patient management of the hepatitis B and c viruses, as well as the human immunodeficiency virus

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness